Back to Trial

Oracle Runs

Oracle findings and outcome history for Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes (NCT07098663).

Runs
4
Findings
4
Latest Run
Apr 6, 2026, 2:08 PM
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial is recruiting with primary completion in Jan 2026. No public efficacy readout or results posted. All sources are protocol descriptions or preclinical only.

Found Apr 6, 2026, 2:08 PMReviewed Apr 6, 2026, 2:19 PM
Web Searchclinicaltrials.gov
Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes
Current status: Recruiting. Estimated primary completion: 2026-01-19. No results posted.
Web Searchtipranks.comOct 27, 2025, 12:00 AM
Mankind Pharma's MKP10241 Study: A Potential Game-Changer for Obesity and Diabetes Treatment?
Ongoing Phase 2a study to assess food effect, safety, tolerability, PK and PD. No efficacy results reported.
NO_DECISIONDismissed90% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov still lists this study as recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:33 PM
ClinicalTrialsclinicaltrials.govSep 29, 2025, 12:00 AM
Study Details | NCT07098663 | ClinicalTrials.gov
ClinicalTrials.gov lists recruiting; primary completion 2026-01-19; hasResults=false on the latest posted update.
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific public readout found. Registry-style sources show NCT07098663 was still recruiting with estimated primary completion on 2026-01-19 and study completion on 2026-04-17, while sponsor materials still describe MKP10241 only as being in Phase 2/early Phase 2 development, not as having reported results.

Found Apr 3, 2026, 4:02 PMReviewed Apr 3, 2026, 4:47 PM
ClinicalTrialsichgcp.netOct 1, 2025, 12:00 AM
MKP10241 in Obesity and Type 2 Diabetes Mellitus (T2DM) and Safety and Tolerability - Clinical Trials Registry - ICH GCP
Lists NCT07098663 with study start Aug 12, 2025, estimated primary completion Jan 19, 2026, estimated study completion Apr 17, 2026, and notes study record/results posting is tracked separately.
Sponsormankindpharma.comSep 8, 2025, 12:00 AM
Mankind Pharma Gets CDSCO Nod to Begin Phase 1 Trials of Novel Autoimmune Drug Candidate MKP11093
Sponsor says another pipeline candidate, MKP10241, completed Phase 1 and is currently in Phase 2 development for obesity and diabetes; no Phase 2 data readout is disclosed.
Sponsormankindpharma.com
Innovative Drug Discovery at Mankind Pharma | Advancing Medical Research
Sponsor R&D page says MKP10241 is currently in early phase II trials in India/abroad, again without any trial-specific efficacy or safety results for NCT07098663.
NO_DECISIONDismissed92% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific public Phase 2 readout was found. The cited sources describe NCT07098663/MKP10241 as an ongoing early Phase 2 study and, as of September 2025, still in Phase 2 development. Without a clear public efficacy/safety interpretation for this exact trial, outcome cannot be classified positive or negative.

Found Apr 1, 2026, 6:38 PMReviewed Apr 1, 2026, 6:46 PM
ClinicalTrialsichgcp.netSep 24, 2025, 12:00 AM
MKP10241 in Obesity and Type 2 Diabetes Mellitus (T2DM) and Safety and Tolerability
Registry entry for NCT07098663 describes an ongoing Phase 2a placebo-controlled study assessing food effect, safety, tolerability, PK and PD of MKP10241; no trial readout or interpreted results are presented.
Sponsormankindpharma.com
New Drug Discovery Research (NDDR) | Mankind Pharma
Sponsor pipeline page says MKP10241 is currently in early phase II trials in India/abroad, indicating the program is still ongoing rather than publicly read out.
Sponsormankindpharma.comSep 8, 2025, 12:00 AM
Mankind Pharma Gets CDSCO Nod to Begin Phase 1 Trials of Novel Autoimmune Drug Candidate MKP11093
Sponsor press release states MKP10241 has completed Phase 1 and is currently in Phase 2 development for obesity and diabetes; it does not report Phase 2 results for NCT07098663.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.